Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells

Prostate

Volumn 68, Issue 6, 2008, Pages 679-689

  Mabjeesh, Nicola J ^a   Shefler, Alexander ^b   Amir, Sharon ^a   Matzkin, Haim ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

2 methoxyestradiol; EtA receptor antagonist; Hypoxia inducible factor; Prostate cancer; Synergism

Indexed keywords

2 METHOXYESTRADIOL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE;

ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; OSTEOBLASTS; PEPTIDES, CYCLIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ENDOTHELIN; RNA, MESSENGER;

EID: 42949161993     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20734     Document Type: Article

References (58)

1. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, Mooberry SL. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 2003;63:1538-1549.
2. Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 2003;15:425-430.
3. Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Stahl WL. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005;65:141-150.
4. Dubey RK, Imthurn B, Jackson EK. 2-Methoxyestradiol: A potential treatment for multiple proliferative disorders. Endocrinology 2007;148:4125-4127.
5. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002;62:3691-3697.
6. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
7. Semenza GL. Targeting, HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
8. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26.
9. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 2004;30:465-468.
10. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 2005;242:157-213.
11. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007;22:559-572.
12. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-6633.
13. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-27.
14. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41-48.
15. Burke PA, Swartz GM, Hanson AD, Chen B, Agoston GE, Shah J, Suwandi L, Fogler WE, Treston AM, Lavallee TM. 2-Methoxyestradiol analog 883 shows improved anti-tumor activity in vitro with increased survival and reduced tumor burden in vivo. AACR Meeting Abstracts 2005; 2005:1376-a.
16. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BV, Reed MJ, Purohit A. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 2006; 66:324-330.
17. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372.
18. Mueck AO, Seeger H, Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol? Life Sci 2004;75:1205-1210.
19. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 2004;10:8665-8673.
20. Han GZ, Liu ZJ, Shimoi K, Zhu BT. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 2005;65:387-393.
21. Clark EA, Hills PM, Davidson BS, Wender PA, Mooberry SL. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 2006;3:457-467.
22. Nelson JB. Endothelin receptor antagonists in the treatment of prostate cancer. Prostate 2001;49:91-92.
23. Godara G, Cannon GW, Cannon GM Jr, Bies RR, Nelson JB, Pflug BR. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005;65:27-34.
24. Nelson JB. Endothelin receptor antagonists. World J Urol 2005;23:19-27.
25. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-949.
26. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12:6296s-6300s.
27. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689.
28. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001;37:640-644.
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
31. Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 2006;66:856-866.
32. Satcher RL Jr, Dvorkin K, Levenson AS, Vandenbroek T, Stupp SI. Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis. Clin Orthop Relat Res 2004:54-63.
33. Harris SA, Enger RJ, Riggs BL, Speisberg TC. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 1995;10:178-186.
34. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6376.
35. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-1807.
36. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicinebinding site. J Med Chem 1995;38:2041-2049.
37. Kumar AP, Garcia GE, Slaga TJ. 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001;31:111-124.
38. Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001;285:1259-1266.
39. Kobayashi S, Tang R, Wang B, Opgenorth T, Langenstroer P, Shapiro E, Lepor H. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol 1994;45:306-311.
40. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 2007;14:233-244.
41. Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H. Localization of endothelin receptors in the human prostate. J Urol 1994;151:763-766.
42. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
43. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063-1069.
44. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97:779-784.
45. Axanova L, Morre DJ, Morre DM. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett 2005;225:35-40.
46. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 2002;20:173-182.
47. Fisher M. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer. Clin Prostate Cancer 2002;1:79-80.
48. Lee D. Clinical trials of atrasentan in hormone-refractory prostate cancer. Clin Prostate Cancer 2003;2:84-86.
49. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169:1143-1149.
50. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, Pflug BR. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8:725-732.
51. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67:3818-3826.
52. Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosano L, Spinella F, Bagnato A. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002;103 (Suppl 48):302S-305S.
53. Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003;63:2447-2453.
54. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002;62:6381-6384.
55. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-3968.
56. Gokmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr. Beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 2005;65:9406-9414.
57. He S, Dibas A, Yorio T, Prasanna G. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells. Exp Biol Med (Maywood) 2007;232:370-384.
58. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002;277:27850-27855.